U.S. alternative investment firm Bain Capital plans to acquire Singapore-based DSM Sinochem Pharmaceuticals (DSP), supplier of sustainable antibiotics, next-generation statins and anti-fungals.
A deal for the closely held business DSP could fetch about 600 million euros ($698 million), including payments.
DSP is a 50/50 Joint Venture of Royal DSM, a global science-based company in Nutrition, Health and Sustainable Living, and Sinochem Group.
The joint venture was formed in 2010, when DSM sold a 50 percent stake in its penicillin operation to Sinochem Group, ending a six year-search for a partner.